Michigan Senate bills would make insurers cover insulin, EpiPens, inhalers without co-pay
Michigan State Senators Darrin Camilleri and Chedrick Greene introduced bills requiring insurers to cover insulin, EpiPens, inhalers, and related supplies without co-pays, citing rising drug costs as a barrier to access. The Michigan Association of Health Plans opposes the measure, arguing it could impact premiums, while lawmakers emphasize the legislation’s potential to reduce hospital strain and protect vulnerable populations.
Two Michigan State Senators introduced legislation Wednesday to eliminate co-pays for critical medications, including insulin, EpiPens, inhalers, and related supplies like monitors and test strips. State Sen. Darrin Camilleri (D-Trenton) and Sen. Chedrick Greene (D-Saginaw) argued that high costs for life-saving drugs disproportionately burden patients with diabetes, asthma, or severe allergies, often forcing difficult budget choices. Their bills would require insurers to fully cover these essential items, ensuring uninterrupted access without financial strain. The proposal aims to prevent hospitalizations by ensuring patients can afford necessary treatments, Greene stated, calling it a matter of common sense for vulnerable residents. Camilleri highlighted personal experience, noting his son’s reliance on an EpiPen and the recurring co-pay burden even for unused medications. Insurers, represented by the Michigan Association of Health Plans, have not yet endorsed the measure, citing concerns over potential impacts on premiums and drug pricing. The association pledged to review the bills thoroughly before engaging in discussions with lawmakers. The legislation faces an uncertain path in the Republican-controlled Michigan House, where Speaker Rep. Matt Hall (R-Richland Township) has not yet reviewed the proposal. Camilleri acknowledged past challenges in passing drug affordability bills but emphasized the urgency of addressing prescription costs. The bills will now proceed to committee for further consideration, with insurers and lawmakers set to debate their implications on patient access and healthcare costs. Supporters argue the measure aligns with trends in other states that have capped co-pays for essential medications, framing it as a step toward equitable healthcare access. Opponents, however, warn that removing co-pays could lead to higher premiums or reduced coverage for other drugs. The debate underscores broader tensions between patient affordability and insurer financial sustainability in Michigan’s healthcare system.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.